Navigation Links
Echo Therapeutics, Inc. Announces 2011 Financial Results

PHILADELPHIA, March 16, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced financial results for the year ended December 31, 2011.  Echo's Annual Report on Form 10-K is available through Echo's website at

2011 Corporate Highlights:

  • Echo added key executives to its management team as part of the company's plan to accelerate the development and commercialization of Symphony and other new products contemplated in its growth strategy.
  • Echo's common stock began trading on the Nasdaq Capital Market in June, providing more liquidity to its shareholders and increased visibility to the investment community over the short and long-term.
  • Echo successfully completed two clinical trials of Symphony in patients with and without diabetes that showed that Symphony successfully monitors patient glucose levels and has the potential to be an important tool for the tracking and trending of glucose.  To date, Echo has completed eight positive pilot studies of Symphony with a combined average error rate, often referred to as mean absolute relative difference (MARD), of 12.4%.
  • Echo announced multiple patents and trademark grants throughout the year that will provide its products with long-term market protection.  Echo has obtained 12 U.S. patents and 42 foreign patents, and has 39 patent applications pending in the U.S. and foreign countries.

  • "We made very tangible progress during 2011 and we achieved some very important milestones. We believe the clinical data from the most recent trials further demonstrates Symphony's significance and potential for the monitoring of glucose levels," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics.  "Additionally, we raised significant capital through a series of private financings and warrant exercises that brought our year-end cash position to nearly $9 million.  With a strengthened and simplified balance sheet, and an experienced management team, Echo is focused on the continued, accelerated pace of product development finalization and clinical validation necessary for regulatory clearance of the Symphony tCGM System in both Europe and the U.S."

    Fiscal Year 2011 Financial ResultsFor fiscal year 2011, the Company was principally involved with the product development and clinical studies of its Symphony tCGM System. Echo reported approximately $447,000 in total revenues during 2011 compared to $428,000 during 2010.  Operating expenses for 2011 of $8.7 million increased by approximately $3.4 million compared to 2010 reflecting our increased investment in product development and corporate structure.  The net loss for 2011 was $16.7 million, or ($0.49) per share, compared to a net loss of $4.3 million, or ($0.15) per share for 2010.  The Company reported a cash balance of approximately $9.0 million as of December 31, 2011.

    2012 Development Outlook"We believe that the significant accomplishments and progress made in 2011 has set the stage for an exciting and productive 2012.  Building on the positive momentum of the previous two Symphony studies, we anticipate positive results from our current critical care study in the near term," Dr. Mooney concluded. "This year we are focused on completing several key milestones that we believe will clear the path toward commercialization of Symphony and will significantly increase shareholder value."

    Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

    For More Information:
    Christine H. Olimpio
    Director, Investor Relations and Corporate Communications
    (215) 717-4104

    Connect With Us:
    - Visit our website at
    - Follow us on Twitter at
    - Join us on Facebook at Therapeutics, Inc.Condensed Consolidated Balance SheetsDecember 31,2011December 31,2010ASSETSCurrent Assets:Cash and cash equivalents

    ,342,044Other current assets

    567,940621,693Total current assets

    9,563,5111,963,737Net property and equipment (including assets under capitalized leases)

    317,73148,034Other Assets:Intangible assets, net of accumulated amortization

    9,625,0009,625,000Restricted cash, deposits and other assets

    20,565275,499Total other assets

    9,645,5659,900,499Total assets

    $  19,526,807$  11,912,270LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable

    5,634Deferred revenue

    123,708405,454Derivative warrant liability

    1,035,3371,544,996Accrued expenses and other liabilities

    968,120565,546Total current liabilities

    2,492,4633,121,630Deferred revenue, notes payable and capital lease obligation, net of current portion

    65,75588,356Total liabilities

    2,558,2183,209,986CommitmentsStockholders' Equity:Perpetual redeemable preferred stock, Series B

    -2Convertible preferred stock, Series C & D

    30,16049Common stock

    385,442311,264Additional paid-in capital

    98,116,32779,646,385Common stock subscribed for but not paid for or issued

    6,667285,000Accumulated deficit

    (81,570,007)(71,540,416)Total stockholders' equity

    16,968,5898,702,284Total liabilities and stockholders' equity

    $  19,526,807$  11,912,270Condensed Consolidated Statements of OperationsYears Ended December 31,20112010Licensing revenue

    225,868Other revenue

    145,152202,592Total revenues

    447,211428,460Operating Expenses:Research and development

    3,796,1272,578,852Selling, general and administrative

    4,905,7572,760,062Total operating expenses

    8,701,8845,338,914Loss from operations

    (8,254,673)(4,910,454)Other Income (Expense):Interest income (expense), net

    (9,118)(36,030)Gain (loss) on extinguishment of debt/payables

    (1,514)183,863Gain (loss) on disposal of assets

    (1,348)-Qualified therapeutic research grant

    -244,480Derivative warrant liability gain (loss)

    (1,762,938)371,345Other income (expense), net

    (1,774,918)763,658Net loss

    (10,029,591)(4,146,796)Accretion of dividends on Series B Convertible Perpetual
    Redeemable Preferred Stock

    (157,733)(131,659)Deemed dividend on beneficial conversion feature of Series D Convertible Preferred Stock

    (1,975,211)-Deemed dividend on warrant repricings

    (4,559,761)-Net loss applicable to common shareholders

    $  (16,722,296)$
    (4,278,455)Net loss per common share, basic and diluted

    (0.15)Basic and diluted weighted average common shares outstanding


    SOURCE Echo Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
    2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
    3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
    4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
    5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
    6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
    7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
    8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
    9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
    10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
    11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
    Post Your Comments:
    (Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
    (Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
    (Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
    (Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
    (Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
    (Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
    (Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
    Breaking Medicine News(10 mins):